CLDX - Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
Story updates
10:59:51 AM UTC
SquawkNews
Celldex Announces Positive Results From Phase 3 Embarq-Csu1 And Embarq-Csu2 Studies Of Barzolvolimab Which Met Primary And All Key Secondary Endpoints
11:02:07 AM UTC
SquawkNews
Celldex reported positive topline results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 in antihistamine-refractory CSU, meeting the primary UAS7 endpoint at Week 12 and all key secondary endpoints, with favorable safety through Week 24. A BLA submission is planned for 2027.Material DetailsContext by AI…